Evidence map›Paper›PMID 33959478›Full record

ArticleWorld journal of clinical oncology2021

Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil.

Kosuke Suzuki, Tsuyoshi Etoh, Tomotaka Shibata, Kohei Nishiki, Shoichi Fumoto, Yoshitake Ueda, Hidefumi Shiroshita, Norio Shiraishi, Masafumi Inomata

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kosuke SuzukiDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan. kosuzuki@oita-u.ac.jp.
Tsuyoshi EtohDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan.
Tomotaka ShibataDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan.
Kohei NishikiDepartment of Surgery, Oita Nakamura Hospital, Oita 870-0022, Japan.
Shoichi FumotoDepartment of Surgery, Oita Nakamura Hospital, Oita 870-0022, Japan.
Yoshitake UedaDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan.
Hidefumi ShiroshitaDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan.
Norio ShiraishiDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan.
Masafumi InomataDepartment of Gastroenterological and Pediatric Surgery, Oita University, Yufu 879-5593, Oita, Japan.
Oita University · JPNakamura Memorial Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

aimTo evaluate the value of PET complete metabolic response (CMR) as a prognostic predictor for esophageal cancer.

methodsBetween June 2013 and December 2017, 58 patients with squamous cell esophageal cancer who underwent neoadjuvant chemotherapy (NAC) in Oita University were enrolled in this retrospective cohort study. Tumors were clinically staged using fluorodeoxyglucose-PET/computed tomography before and after NAC. After NAC, maximal standardized uptake value ≤ 2.5 was defined as PET-CMR, and maximal standardized uptake value > 2.5 was defined as non-PET-CMR. We compared short-term outcomes between the PET-CMR group and non-PET-CMR group and evaluated prognostic factors by univariate and multivariate analyses.

resultsThe PET-CMR group included 22 patients, and the non-PET-CMR group included 36 patients. There were no significant differences in intraoperative and postoperative complications between the two groups. Five-year relapse-free survival and overall survival in the PET-CMR group were significantly more favorable than those in the non-PET-CMR group (38.6 mo

conclusionPET-CMR after NAC is considered a favorable prognostic factor for esophageal cancer. Evaluation by PET-computed tomography could be useful in clinical decision making for esophageal cancer.

Indexed as

Complete metabolic responseDocetaxel, cisplatin plus 5-fluorouracilEsophageal cancerNeoadjuvant chemotherapyPositron emission tomography/computed tomographyPrognostic factor

Identifiers

PMID33959478
PMCPMC8085515
OpenAlexW3153315238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.